Pediatrics

Nirsevimab (Beyfortus) is the first respiratory syncytial virus (RSV) preventative drug to be approved by the FDA, and can protect infants through their first RSV season for up to 5 months.

It is the first vaccine of its kind to be FDA approved, and it met multiple safety and efficacy standards through clinical trials.

The results differ from previous studies and the predictions of the researchers that the Child Tax Credit would reduce the prevalence of low birth weight among pregnant women across the country.

Guidelines from the American Academy of Pediatrics recommend treating obesity as a chronic illness.

The findings of the study demonstrate the need for preventive interventions for all infants in order to reduce the burden of severe illness from respiratory syncytial virus lower respiratory tract infections.

Key study finding shows associations between the beat frequency in the rhythmic stimulus in the frontal left sites of infant brains and pathways related to brain modulation and nucleotide levels.

Prior to this study, anti-platelet factor 4 disorder was thought to be caused by exposure to heparin or autoimmune conditions.

Many studies with a stated goal of advancing child health care in administratively-defined minors have no clinical value and may even harm young patients.

Approximately 57% of individuals who were shown a flowchart of the FDA vaccine approval process were very or somewhat likely to recommend a respiratory syncytial virus vaccine to a pregnant family member or friend compared to only 40% of those who were not shown the process.

After repeated treatment with packed red blood cell transfusions, treatment with intravenous immunoglobulin in a child with parvovirus B19 infection successfully resolved the infection and negated the need for further transfusions.

A bit of preparation can set children up for success and reduce the stress of this busy time.

Updated guidelines, comprehensive review, and an investment of resources into pediatric preventive cardiology programs could help provide successful care.

CDC Advisory Committee on Immunization Practices voted 10 to 0 to recommend the routine use of nirsevimab-alip (Beyfortus; Sanofi and AstraZeneca) for the prevention of respiratory syncytial virus lower respiratory tract disease in newborns and infants.

The approval marks the first monoclonal antibody approved to protect all infants through their first respiratory syncytial virus season.

The phase 3 S1826 trial is the largest Hodgkin lymphoma study in NCTN history.

Pharmacists can help patients live a life of meaning and gratitude after cancer recovery.

Pediatric drug development, which has a complex background and history, has fundamental catches based around how children are defined in the context of clinical studies.

The gene-editing technology has been used successfully in a pediatric patient with T-cell ALL.

The vaccine was 88% effective at preventing pertussis among infants younger than 2 months when administered during the third trimester of pregnancy.

Pediatric guidelines suggest 10 days of therapy for community-acquired pneumonia, but recent data support shortening therapy duration.

Analysis from the Johns Hopkins Children’s Center and University of Colorado indicates that cancellation of sports and a switch to virtual learning likely increased this risk.

Analysis shows that myocarditis was the most commonly diagnosed condition associated with pediatric post-acute sequelae of SARS-CoV-2.

Analysis is based on previously reported data collected in March and April 2022, with the FDA granting emergency use authorization for individuals aged 6 months to 4 years on June 17.

Investigators from University of Texas Health Science Center at Houston analyze data from individuals aged 5 to 18 years enrolled in the Texas CARES survey.

Pharmacists can help familiarize young patients with the vaccinations appropriate for pediatric use.

Phase 3 study follows recent approval of the drug for the same condition in individuals aged 12 years and older who weight at least 40 kg.

Individuals randomized to receive dabrafenib and trametinib had a statistically significant overall response rate of 47% compared with 11% for those who received chemotherapy.

Case highlights the need to stop, listen, and investigate when patients or parents express a safety concern.

Approximately one-third of parents said their children are picky, and another third said they don’t think their children eat enough fruits and vegetables.

Analysis provides new understanding of the effect of probiotics on the tiniest of infants in the neonatal intensive care.